Chyrek-Borowska S, Siergiejko Z, Południewska B
Kliniki Alergologii AM w Białymstoku.
Pneumonol Alergol Pol. 1994;62(1-2):56-63.
The efficacy and safety of Horacort in the treatment of patients with asthma and allergic rhinitis were assessed. The studies were carried out on the group of 47 patients, 32 with mild to moderate bronchial asthma and 15 patients suffering from allergic seasonal or perrenial rhinitis. The asthmatic patients after two weeks run-in period were treated with Horacort (2 puffs bd) during eight weeks. Following randomly selected 16 persons were treated with Pulmicort and other 16 persons took placebo. Patients suffering from allergic rhinitis after one week run-in period were treated with Horacort (2 puffs bd) during four weeks and following with placebo during a next month. The excellent and good clinical results were observed in above 75% patients with bronchial asthma and allergic rhinitis. We observed a decrease in symptoms score, bronchial hyperreactivity, fenoterol consumption, eosinophil number and increase in spirometric parameters. A tolerance of Horacort was very good, only two patients in asthma group had a hoarseness and one with rhinitis epistaxis during therapy.
评估了Horacort治疗哮喘和过敏性鼻炎患者的疗效和安全性。对47例患者进行了研究，其中32例为轻度至中度支气管哮喘患者，15例为患有季节性或常年性过敏性鼻炎的患者。哮喘患者经过两周的导入期后，接受Horacort治疗（每日两次，每次2喷），为期八周。随后随机选择16人接受普米克治疗，另外16人服用安慰剂。患有过敏性鼻炎的患者经过一周的导入期后，接受Horacort治疗（每日两次，每次2喷），为期四周，接下来的一个月服用安慰剂。在超过75%的支气管哮喘和过敏性鼻炎患者中观察到了良好和优秀的临床效果。我们观察到症状评分、支气管高反应性、非诺特罗用量、嗜酸性粒细胞数量下降，以及肺功能参数增加。Horacort的耐受性非常好，哮喘组只有两名患者在治疗期间出现声音嘶哑，一名鼻炎患者出现鼻出血。
